|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Current assets: | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Accounts receivable | ||||||||||||||||||||
| Receivable due from Roche | ||||||||||||||||||||
| Inventory | ||||||||||||||||||||
| Prepaid expenses and other current assets | ||||||||||||||||||||
| Total current assets | ||||||||||||||||||||
| Marketable securities | ||||||||||||||||||||
| Property and equipment, net | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities and stockholders’ (deficit) equity | ||||||||||||||||||||
| Current liabilities: | ||||||||||||||||||||
| Accounts payable | ||||||||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||||||||
| Deferred revenue | ||||||||||||||||||||
| Roche related-party deferred revenue | ||||||||||||||||||||
| Current portion of deferred rent | ||||||||||||||||||||
| Total current liabilities | ||||||||||||||||||||
| Deferred rent, net of current portion and other non-current liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Indebtedness to Roche - non-current | ||||||||||||||||||||
| Stockholders’ (deficit) equity: | ||||||||||||||||||||
| Common stock, $0.0001 par value, 150,000,000 shares authorized; 37,147,273 and 36,541,770 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Total stockholders’ (deficit) equity | ||||||||||||||||||||
| Total liabilities and stockholders’ (deficit) equity | ||||||||||||||||||||
Loading...
